Related Experiment Video

Updated: Aug 15, 2026

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Structure-based design of novel anti-cancer agents targeting aurora kinases

Daruka Mahadevan1, David J Bearss, Hariprasad Vankayalapati

  • 1Arizona Cancer Center, Division of Hematology/Oncology and Division of Medicinal Chemistry, University of Arizona, 1515, N. Campbell Avenue, Tucson, AZ 85724, USA. dmahadevan@azcc.arizona.edu

Current Medicinal Chemistry. Anti-Cancer Agents
|April 8, 2003
PubMed

Insights

Aurora kinases are oncogenes overexpressed in many cancers. This study validates ARK1 as a drug target in pancreatic cancer using structure-based inhibitor design.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Aurora kinases are serine-threonine kinases overexpressed in various solid tumors.
  • These kinases play critical roles in cell division processes like chromosome segregation and cytokinesis.
  • Dysregulation of Aurora kinases is linked to oncogenesis.

Purpose of the Study:

  • To validate human ARK1 (Aurora2, STK15, HsAIRK1) as a druggable target for pancreatic cancer treatment.
  • To explore structure-based approaches for designing specific ARK1 inhibitors.

Main Methods:

  • Utilized homology modeling to create a structural model of ARK1.
  • Employed affinity docking to identify potential inhibitor binding sites.
  • Conducted in vitro kinase assays to test inhibitor efficacy iteratively.

Main Results:

  • Demonstrated the feasibility of structure-based design for ARK1 inhibitors.
  • Provided a framework for iterative optimization of drug candidates.
  • Highlighted ARK1's potential as a therapeutic target in pancreatic cancer.

Conclusions:

  • Human ARK1 is a validated druggable target for pancreatic cancer.
  • Structure-based inhibitor design is a viable strategy for targeting Aurora kinases.
  • Targeting ARK1 may offer a novel therapeutic approach for pancreatic cancer and other malignancies.

More Related Videos

Real-Time Monitoring of Aurora kinase A Activation using Conformational FRET Biosensors in Live Cells06:29

Real-Time Monitoring of Aurora kinase A Activation using Conformational FRET Biosensors in Live Cells

Published on: July 30, 2020

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...